Gastrin-releasing peptide promotes the growth of HepG2 cells via EGFR-independent ERK1/2 activation

Oncology Reports

Volumn 24, Issue 2, 2010, Pages 441-448

  Li, Xinqiu ^a   Lv, Yunfu ^a,b   Yuan, Aihua ^c   Yi, Shanyong ^a   Ma, Yong ^c   Li, Zongfang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b HAINAN PROVINCIAL PEOPLE S HOSPITAL   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Extracellular signal regulated kinase 1 2; Gastrin releasing peptide; Gastrin releasing peptide receptor; Hepatocellular carcinoma; Mitogen activated protein kinase

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GASTRIN RELEASING PEPTIDE; GASTRIN RELEASING PEPTIDE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; 4-((3-BROMOPHENYL)AMINO)-6,7-DIMETHOXYQUINAZOLINE; ANTINEOPLASTIC AGENT; BOMBESIN RECEPTOR; EGFR PROTEIN, HUMAN; INDOLE DERIVATIVE; MAPK1 PROTEIN, HUMAN; PD 176252; QUINAZOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL INTERACTION; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LIVER CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DRUG EFFECTS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; HEPG2 CELL LINE; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELLS, CULTURED; ENZYME ACTIVATION; GASTRIN-RELEASING PEPTIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; INDOLES; LIVER NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, BOMBESIN;

EID: 77954361468     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000877     Document Type: Article

References (22)

1. Patel O, Shulkes A and Baldwin GS: Gastrin-releasing peptide and cancer. Biochim Biophys Acta 1766: 23-41, 2006.
2. Qu X, Xiao D and Weber HC: Biologic relevance of mammalian bombesin-like peptides and their receptors in human malignancies. Curr Opin Endocrinology Diabetes 10: 60-71, 2003.
3. Hajri A, Balboni G, Koenig M, Garaud JC and Damge C: Gastrin-releasing peptide: in vivo and in vitro growth effects on an acinar pancreatic carcinoma. Cancer Res 52: 3726-3732, 1992.
4. Yano T, Pinski J, Groot K and Schally AV: Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines. Cancer Res 52: 4545-4547, 1992.
5. Constantinides C, Lazaris AC, Haritopoulos KN, Pantazopoulos D, Chrisofos M and Giannopoulos A: Immunohistochemical detection of gastrin releasing peptide in patients with prostate cancer. World J Urol 21: 183-187, 2003.
6. Saurin JC, Rouault JP, Abello J, Berger F, Remy L and Chayvialle JA: High gastrin releasing peptide receptor mRNA level is related to tumour dedifferentiation and lymphatic vessel invasion in human colon cancer. Eur J Cancer 35: 125-132, 1999.
7. Fang MZ, Liu C, Song Y, et al: Overexpression of gastrinreleasing peptide in human esophageal squamous cell carcinomas. Carcinogenesis 25: 865-871, 2004. (Pubitemid 38886072)
8. Kelley MJ, Linnoila RI, Avis IL, et al: Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest 112: 256-261, 1997.
9. Cornelio DB, Roesler R and Schwartsmann G: Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol 18: 1457-1466, 2007. (Pubitemid 47365477)
10. Zhou J, Chen J, Mokotoff M, Zhong R, Shultz LD and Ball ED: Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer. Clin Cancer Res 9: 4953-4960, 2003. (Pubitemid 37323302)
11. Qiao J, Kang J, Ishola TA, Rychahou PG, Evers BM and Chung DH: Gastrin-releasing peptide receptor silencing suppresses the tumorigenesis and metastatic potential of neuroblastoma. Proc Natl Acad Sci USA 105: 12891-12896, 2008.
12. Parry JJ, Andrews R and Rogers BE: MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor. Breast Cancer Res Treat 101: 175-183, 2007.
13. Wiele CV, Phonteyne P, Pauwels P, et al: Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry. J Nucl Med 49: 260-264, 2008.
14. SchweinsbergC, Maes V, Brans L, et al: Novel glycated [99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors. Bioconjug Chem 19: 2432-2439, 2008.
15. Lui VW, Thomas SM, Zhang Q, et al: Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene 22: 6183-6193, 2003.
16. Chen PW and Kroog GS: Alterations in receptor expression or agonist concentration change the pathways gastrin-releasing peptide receptor uses to regulate extracellular signal-regulated kinase. Mol Pharmacol 166: 1625-1634, 2004.
17. Zhang Q, Thomas SM, Lui VW, et al: Phosphorylation of TNF-α converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci USA 103: 6901-6906, 2006.
18. Thomas SM, Grandis JR, Wentzel AL, Gooding WE, Lui VW and Siegfried JM: Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells. Neoplasia 7: 426-431, 2005.
19. Seglen PO, Skomedal H, Saeter G, Schwarze PE and Nesland JM: Neuroendocrine dysdifferentiation and bombesin production in carcinogen-induced hepatocellular rat tumours. Carcinogenesis 10: 21-25, 1989. (Pubitemid 19032078)
20. Breuhahn K, Longerich T and Schirmacher P: Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 25: 3787-3800, 2006.
21. Tsuboi Y, Ichida T, Sugitani S, et al: Overexpression of extracellular signal-regulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma. Liver Int 24: 432-436, 2004.
22. Schmitz KJ, Wohlschlaeger J, Lang H, et al: Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 48: 83-90, 2008.